Overview

Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain

Status:
Completed
Trial end date:
2018-05-02
Target enrollment:
0
Participant gender:
All
Summary
A Randomized, Double-blind, Active-Controlled, Multi-center, Phase 3 Trial to Compare the Safety and Efficacy between YHD1119 and Pregabalin in Patients with Peripheral Neuropathic Pain
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yuhan Corporation
Treatments:
Pregabalin
Criteria
Inclusion Criteria:

- Signed Informed Consent

- HbA1c ≤ 9.5% diabetes mellitus patients with pain over 6 months in Diabetic Peripheral
Neuropathy or postherpetic Neuralgia patients at least 3 months pain after diagnosis
of skin rash due to herpes zooster

Exclusion Criteria:

- Have Brittle diabetes mellitus